Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative - 05/08/11
Résumé |
Background |
Glycoprotein (GP) IIb/IIIa inhibitors can improve outcomes in patients with non–ST-segment elevation acute coronary syndromes but raise the risk of bleeding, particularly if dosed in excess. The impact of GP IIb/IIIa dosing feedback on safety and major bleeding is unknown.
Methods |
Glycoprotein IIb/IIIa dosing feedback was added to the CRUSADE quarterly site reports in the first quarter of 2006. We describe GP IIb/IIIa use and dosing among 25,641 patients with non–ST-segment elevation acute coronary syndromes from the fourth quarter of 2005 to the fourth quarter of 2006.
Results |
Eleven thousand eight hundred forty-six patients received GP IIb/IIIa inhibitors, including 4,031 women and 2,609 elderly patients (age, ≥75 years). Among GP IIb/IIIa–treated patients, unadjusted rates of excess GP IIb/IIIa dosing declined overall (26.4%-22.4%, Ptrend = .01) and among the elderly (65.6%-52.1%, Ptrend < .001). After adjustment, declines in excess dosing remained significant only for the elderly, although more than half of GP IIb/IIIa-treated elderly patients continued to receive excess dosing at the end of the study period (64.1%-51.3%, Ptrend < .001). There were concurrent declines in unadjusted major bleeding rates overall (9.6%-8.0%, Ptrend = .02), but declines among women (14.4%-11.5%, Ptrend = .08) and the elderly (17.1%-11.0%, Ptrend = .05) did not reach statistical significance. After adjustment for baseline characteristics and excess dosing, declines in major bleeding rates were no longer significant overall or for any subgroup.
Conclusion |
Within 9 months of initiating a safety feedback program, we observed early decreases in excess GP IIb/IIIa dosing among the elderly but minimal changes in excess dosing overall. Further work is needed to promote safe and effective medication use in vulnerable patients who are most at risk of harm.
Le texte complet de cet article est disponible en PDF.Plan
Vol 160 - N° 6
P. 1072-1078 - décembre 2010 Retour au numéro
Article précédent
- The prognostic importance of worsening renal function during an acute myocardial infarction on long-term mortality
- Amit P. Amin, John A. Spertus, Kimberly J. Reid, Xiao Lan, Donna M. Buchanan, Carole Decker, Frederick A. Masoudi
- The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy
- Ton Heestermans, Arnoud W.J. van 't Hof, Jurriën M. ten Berg, Jochem W. van Werkum, Eric Boersma, Arend Mosterd, Pieter R. Stella, Arthur B. van Zoelen, A.T. Marcel Gosselink, Waclav Kochman, Thorsten Dill, Petra C. Koopmans, Gert van Houwelingen, Felix Zijlstra, Christian Hamm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?